Code details & principles for
Code | Description | Chapter/Sub-Chapter | Code Specific Guidance |
---|---|---|---|
M6582 | Transperineal template-guided biopsies of the prostate under image guidance | 12.5.0 Prostate |
CCSD Code (unacceptable combination) | Narrative (unacceptable combination) | Date Code Added |
---|---|---|
BT212 | Insertion of low dose rate radioactive agent (brachytherapy) into prostate tumour | Pre 2025 |
BT213 | Planning, insertion and removal of high dose rate radioactive treatment (brachytherapy) into prostate tumour | Pre 2025 |
BT214 | Planning and insertion of low dose rate radioactive treatment (brachytherapy) into prostate tumour | Pre 2025 |
BT215 | Planning for insertion of low dose rate radioactive treatment (brachytherapy) into prostate tumour | Pre 2025 |
BT222 | Insertion and removal of high dose rate radioactive agent (brachytherapy) into prostate tumour | Pre 2025 |
M6580 | Endoscopic biopsy of prostate (including cystoscopy) | Pre 2025 |
M6583 | Transperineal MRI - US fusion targeted prostate biopsy | Pre 2025 |
M6584 | Transrectal MRI - US fusion targeted prostate biopsy | Pre 2025 |
M7020 | Transrectal sextant needle biopsy of prostate with ultrasound guidance | Pre 2025 |
M7030 | Limited/single core transrectal needle biopsy of prostate +/- ultrasound guidance | Pre 2025 |
These coding principles set out how the authors intend that the codes and narratives within the CCSD Schedule are interpreted and used. The outputs are available to be used by all individual insurers and providers including CCSD and non-CCSD members. Please note that: